Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus
Published: Jul 24, 2023
In an exciting development, Orthogon Therapeutics LLC, a leading player in the field of antiviral therapeutics, has achieved a significant breakthrough. The company's flagship molecule has successfully completed acute toxicity studies, marking a major technical milestone. This achievement has not only garnered praise but also resulted in an additional $3 million investment from its dedicated syndicate of healthcare investors. Over the past year, Orthogon has managed to secure a total financing of $6 million, bringing its overall funding to an impressive $18.5 million.
Dr. Ali H. Munawar, CEO of Orthogon Therapeutics, expressed his delight at this scientific accomplishment as well as the newfound funding. He attributed these successes to the unwavering dedication